Hong Kong stocks' innovative drug concept weakened, with multiple ETFs dropping more than 3%.

Hong Kong stocks of innovative pharmaceutical companies weakened, with more than 3% drop in multiple ETFs. As of press time, Huatai Baoer Hang Seng Innovative Medicine ETF fell by 3.35%, Harvest CSI Hong Kong Stock Connect Innovative Medicine ETF fell by 3.27%, ICBC Credit Suisse Hong Kong Stock Connect Innovative Medicine ETF fell by 3.22%, and GF CSI Hong Kong Innovative Medicine ETF fell by 3.09%.